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Introduction {#sec1}
============

In most cellular contexts Notch signaling acts as a gatekeeper to differentiation, promoting maintenance of stem or progenitor cell fates ([@bib2], [@bib9]). Modulation of Notch signaling is used to control stem or progenitor cell differentiation in vitro, for example toward neural, intestinal, or hematopoietic lineages ([@bib20], [@bib31], [@bib36]). Deregulated Notch signaling is increasingly linked to cancer, and Notch receptor mutations are found in, for example, T cell leukemia, non-small cell lung cancer, and breast cancer as well as in several types of tumor cell lines ([@bib22], [@bib29], [@bib33], [@bib34]). Notch signaling is also frequently hyperactivated in a range of tumors, including breast cancer (for review see [@bib1]).

Notch signaling ensues when transmembrane Notch ligands of the Jagged or Delta-like type interact with Notch receptors on a juxtaposed cell. This results in proteolytic cleavage and liberation of the intracellular domain of the Notch receptor (Notch ICD), which relocates to the cell nucleus and interacts with the DNA-binding protein CSL (also known as RBP-Jk or CBF1), thus making CSL the central node in the signaling cascade for all four Notch receptors (Notch 1--4) ([@bib2]). In the "Notch off" state, CSL acts as a repressor and binds a number of transcriptional co-repressors, such as SHARP/MINT, KDM5A, and KyoT2 (for review see [@bib4]). In the "Notch on" state, i.e., upon binding to Notch ICD, CSL sheds the co-repressors and instead recruits co-activators, such as p300 and PCAF, converting it to an activator. The interaction between Notch ICD and CSL is stabilized by the MAML protein, and the ternary Notch ICD/MAML/CSL complex induces expression of Notch downstream genes ([@bib23], [@bib35]). It has traditionally been assumed that CSL serves as a DNA-bound repressor in the absence of Notch, and in line with this, CSL can bind to DNA in the absence of Notch and remains bound to DNA even during mitosis ([@bib18]). Recent studies, however, provide support for a more dynamic view whereby CSL is recruited to the DNA by Notch ICD ([@bib5], [@bib15]).

It is an open question whether CSL only transmits the signal from the Notch receptors or also plays a role in other, non-Notch-related signaling transductions. Gene-targeting experiments show that phenotypes resulting from targeting of Notch ligands or receptors in some situations are phenocopied by targeting of CSL, for example during somitogenesis ([@bib8], [@bib24]) or in memory T cells ([@bib21]), which is in line with CSL functioning exclusively as the central hub in the Notch signaling cascade ([@bib9]). On the other hand, there are also an increasing number of proteins, such as CTCF, EBNA3c, interferon regulatory factor 4, and RITA (see [@bib7] and references therein), which are not part of the Notch signaling mechanism but interact with CSL, suggesting that CSL has a broader range of actions extending beyond only transmitting Notch signaling.

In this study, we address the question of possible additional roles for CSL and report the unexpected discovery that transplanted breast tumor cells in which CSL was genetically ablated caused rapid tumor growth, a phenotype opposite to blocking Notch function at the receptor level. The phenotype was accompanied by acquisition of a hypoxic response during normoxia and a polyploid giant-cell, cancer stem cell-like, morphology.

Results {#sec2}
=======

Loss of CSL Promotes Tumor Growth In Vivo {#sec2.1}
-----------------------------------------

To explore the role of CSL in a breast tumor context, we targeted both CSL alleles by CRISPR/Cas9 genome editing in MDA-MB-231 cells ([Figure 1](#fig1){ref-type="fig"}A), a breast tumor cell line with active Notch signaling and which promotes tumor growth when transplanted in vivo ([@bib12], [@bib14]). In the two independent MDA-MB-231^CSL−/−^ clones selected for further analysis, there was as expected no detectable CSL protein ([Figure 1](#fig1){ref-type="fig"}B), and the activity of a Notch reporter construct (12x CSL-EGFP) ([@bib11]) was abrogated ([Figure 1](#fig1){ref-type="fig"}C). Reintroduction of CSL into the MDA-MB-231^CSL−/−^ cells restored Notch reporter activity ([Figure 1](#fig1){ref-type="fig"}C) as well as expression of established Notch downstream genes ([Figure S1](#mmc1){ref-type="supplementary-material"}).

Transplantation of the MDA-MB-231^CSL−/−^ cells into the mammary fat pad in mice resulted in accelerated tumor growth compared with control MDA-MB-231^CSL+/+^ cells. The difference was already noticeable after 3 weeks, and after 5 weeks the tumor volume from the MDA-MB-231^CSL−/−^ cells was 2.8 times larger than in the control cell line ([Figures 1](#fig1){ref-type="fig"}D and 1E). Proliferation was increased and apoptosis decreased in the MDA-MB-231^CSL−/−^ tumors as determined by Ki67 ([Figure 1](#fig1){ref-type="fig"}F) and cleaved Caspase-3 ([Figure 1](#fig1){ref-type="fig"}G) staining, respectively. To assess tumor growth potential in an alternative manner, we cultured both CSL-deficient clones on the chorioallantoic membrane in eggs, and tumor growth was robustly enhanced for both clones ([Figure 1](#fig1){ref-type="fig"}H).

In keeping with the tumor data, both CSL^−/−^ clones displayed elevated penetration in a Matrigel invasion assay ([Figure 1](#fig1){ref-type="fig"}I). In a transwell migration assay, clone \#1 showed enhanced migration whereas migration was not significantly changed in clone \#2 ([Figure 1](#fig1){ref-type="fig"}J). Treatment with the γ-secretase inhibitor DAPT, which blocks receptor cleavage and thus Notch1 ICD generation, inhibited cell migration and reduced the invasion of CSL^+/+^ but not of CSL-deficient cells ([Figures 1](#fig1){ref-type="fig"}I and 1J). In conclusion, these data show that removal of CSL enhances tumor growth in vivo and invasiveness in vitro, and exerts an effect distinct from blockade at the Notch receptor level.

Loss of CSL Unleashes a Hypoxic Response under Normoxic Conditions {#sec2.2}
------------------------------------------------------------------

Hypoxia is an important regulator of tumor growth ([@bib13]), and hypoxia and Notch signaling intersect in several ways ([@bib10], [@bib30], [@bib38]). This prompted us to assess whether the hypoxic response was altered in CSL^−/−^ cells. Under normoxic conditions the steady-state level of the transcriptional regulator HIF1α is very low, and HIF1α only becomes stabilized during hypoxia. The two MDA-MB-231^CSL−/−^ clones analyzed above as well as two additional clones showed elevated HIF1α protein levels during normoxia compared with the low levels seen in control cells under normoxia ([Figure 2](#fig2){ref-type="fig"}A; see [Figure S2](#mmc1){ref-type="supplementary-material"}A for quantification). Reintroduction of CSL into the MDA-MB-231^CSL−/−^ cells abrogated the increase in HIF1α protein levels ([Figure S2](#mmc1){ref-type="supplementary-material"}B). The elevated HIF1α protein levels were a result of post-transcriptional events, as the mRNA levels were similar in CSL^+/+^ and CSL^−/−^ cells ([Figure 2](#fig2){ref-type="fig"}B). Activation of hypoxia downstream genes was also observed: in clone \#1, *VEGF-A* gene expression was upregulated, whereas the *STC2* and *KLF8* genes showed elevated expression in clone \#2 ([Figure 2](#fig2){ref-type="fig"}C). In keeping with hypoxia as a potent regulator of tumor vascularization ([@bib28]), vascularization was enhanced around the tumors from CSL^−/−^ cells (data not shown), and collagen IV and CD31 immunostaining (as endothelial markers) in the tumors was elevated ([Figure 2](#fig2){ref-type="fig"}D).

Interaction between endogenous Notch1 ICD and HIF1α was observed in the MDA-MB-231^CSL−/−^ cells ([Figure S2](#mmc1){ref-type="supplementary-material"}C), and blocking Notch ICD generation by DAPT reduced the amount of HIF1α in control cells and to a lesser extent in the CSL-deficient clones under normoxic conditions ([Figure 2](#fig2){ref-type="fig"}E; see [Figure S2](#mmc1){ref-type="supplementary-material"}D for quantification). Under hypoxic conditions HIF1α levels were not altered in control but reduced in CSL-deficient cells following DAPT treatment ([Figure 2](#fig2){ref-type="fig"}E; see [Figure S2](#mmc1){ref-type="supplementary-material"}D for quantification). HIF1α can be stabilized in normoxia and is influenced by nitric oxide and redox potential ([@bib25]), and we therefore investigated whether the normoxically elevated level of HIF1α in the CSL^−/−^ cells was susceptible to the reducing agent DTT. Treatment by DTT resulted in a decrease in HIF1α in CSL^−/−^ cells, as well as in the low level of HIF1α in control cells, during normoxia, whereas HIF1α was largely unresponsive in the hypoxic CSL-deficient cells ([Figure 2](#fig2){ref-type="fig"}F; see [Figure S2](#mmc1){ref-type="supplementary-material"}E for quantification). In conclusion, these data show that HIF1α levels are regulated by CSL.

CSL-Deficient Cells Acquire a Polyploid Giant-Cell Phenotype and a Mitosis Defect {#sec2.3}
---------------------------------------------------------------------------------

Both MDA-MB-231^CSL−/−^ clones were morphologically heterogeneous and presented subcellular populations with a cellular morphology that was distinct from the control cells when cultured in vitro. The phenotype was characterized by cells having a large volume and containing either a giant nucleus or a fragmented polyploid nucleus, and the giant cells were frequently surrounded by small-sized cells ([Figures 3](#fig3){ref-type="fig"}A and 3B). To determine the origin of the giant-cell phenotype, we monitored control and CSL^−/−^ cells by time-lapse live-cell microscopy ([Figure 3](#fig3){ref-type="fig"}C). Single-cell analysis of mitotic progression in both giant and normal-sized cells revealed that a large proportion of CSL^−/−^ cells presented aberrant mitosis, with cells dividing into multiple daughter cells or by exiting mitosis without dividing into two daughter cells ([Figures 3](#fig3){ref-type="fig"}B and 3C, lower panel; videos in [Figure S3](#mmc1){ref-type="supplementary-material"}A). The CSL^−/−^ cells (clone \#2) displayed a decreased proliferation rate in vitro, and reintroduction of CSL restored the proliferation rate observed in control cells ([Figures S3](#mmc1){ref-type="supplementary-material"}B and S3C). In sum, these observations show that loss of CSL affects cell morphology and leads to a mitotic defect.

A Notch-Independent Transcriptional Signature in the CSL-Deficient Cells {#sec2.4}
------------------------------------------------------------------------

We next assessed the transcriptional consequences of CSL deficiency, i.e., whether loss of CSL resulted in only derepression of a Notch transcriptional signature or affected a larger non-Notch-dependent gene set. The Notch transcriptional signature was identified as genes upregulated by ligand activation and where the ligand-induced upregulation was abrogated by blocking Notch receptor cleavage using DAPT. RNA-seq analysis revealed 139 genes that were ligand-activated and sensitive to DAPT, and which we denote the Notch signature ([Figure 4](#fig4){ref-type="fig"}A). This gene set contained a number of well-established Notch downstream targets, such as *HES1*, *HES4*, and *NRARP* ([Figure 4](#fig4){ref-type="fig"}A). We next compared the transcriptomes of MDA-MB-231^CSL−/−^ and control cells, and 1,768 genes were upregulated in the CSL-deficient cells ([Figure 4](#fig4){ref-type="fig"}A). GSEA analysis revealed that this gene set was enriched for genes associated with KRAS and TNFα signaling or involved in angiogenesis, G2M checkpoint or apical junctions, and epithelial-to-mesenchymal transition. In line with this, MMP1 was also significantly upregulated in CSL^−/−^ cells ([Figure S4](#mmc1){ref-type="supplementary-material"}A). A comparison between the 1,768 genes and the 139 genes in the Notch signature revealed that only 47 genes were common to both categories ([Figure 4](#fig4){ref-type="fig"}A). The limited overlap was corroborated by a principal component analysis (PCA) showing that CSL^−/−^ cells clustered quite distinctly from control cells, and that ligand activation and DAPT treatment had quite limited effects on the transcriptomes in the CSL^−/−^ cells, whereas the effect was more profound in the control cells ([Figure 4](#fig4){ref-type="fig"}B).

To assess how CSL deficiency affected the transition from in vitro culture to the in vivo tumor situation, we compared the transcriptome from in vitro culturing with that from tumors at early and late stages after xenografting, using the S^3^ technology to bioinformatically sort out the tumor (human) from the stromal (mouse) transcripts ([@bib6]). PCA revealed that the in vitro transcriptomes from MDA-MB-231^CSL−/−^ and control cells were quite distinct and that the differences were maintained in the tumor situation ([Figure 4](#fig4){ref-type="fig"}C). Interestingly, when tumor cells were excised and returned to in vitro culture the transcriptomes largely reverted back to more closely resemble the respective in vitro transcriptomal profile observed prior to transplantation ([Figure 4](#fig4){ref-type="fig"}C). Finally, single-cell transcriptome analysis showed that MDA-MB-231^CSL−/−^-derived tumors were more homogeneous than MDA-MB-231^CSL+/+^-derived tumors, and cellular homogeneity further increased at the later tumor stage ([Figure 4](#fig4){ref-type="fig"}D). In sum, these data suggest that CSL transcriptionally controls a number of genes that are not part of a core Notch signature.

Discussion {#sec3}
==========

CSL serves as the central node in canonical Notch signaling by transmitting signaling from all Notch receptors upon ligand activation. In this work, we report that genetic ablation of CSL in breast tumor cells leads to enhanced tumor growth after transplantation into mammary fat pads in mice, an unexpected finding given that blocking of Notch at the receptor level reduces and activation of Notch promotes tumor growth ([@bib3], [@bib32]).

The genome-wide transcriptome data support the view that CSL does not merely mediate Notch signaling, as the set of genes upregulated by CSL ablation was considerably larger than the Notch signature in the MDA-MB-231 cells. This conclusion differs from a recent report, which used small hairpin RNA to knock down CSL expression in MDA-MB-231 cells ([@bib16]). While [@bib16], like us, showed that reduced CSL expression in MDA-MB-231 cells promotes tumor growth, they argue that the observed phenotype was linked to derepression of Notch-activated genes. This notion, however, was based on gene-expression analysis of a set of only 170 genes that were on theoretical grounds considered to be Notch responsive ([@bib16]). Only five of the 170 genes, however, were among the 1,768 genes upregulated in the CSL^−/−^ cells and only two genes were common to the 139 genes in our Notch signature ([Figures S4](#mmc1){ref-type="supplementary-material"}B and S4C). The notion that CSL has Notch-independent functions is in line with the fact that CSL interacts with a number of proteins that are not linked to Notch signaling, such as CTCF, EBNA3c, interferon regulatory factor 4, and RITA ([@bib7]). One hypothesis to explain the large Notch-independent gene set posits that CSL binds to a larger number of genomic sites, only a subset of which can bind Notch ICD, and loss of CSL would thus lead to derepression also of Notch-independent genes. Recent data, however, support a view whereby CSL is dynamically recruited by Notch ICD and not statically bound as a repressor ([@bib5], [@bib15]). An alternative hypothesis is that CSL may not directly repress all genes whose expression is altered, but rather control expression of a smaller set of chromatin modifiers or transcriptional regulators, which in turn reset the chromatin landscape and/or alter gene expression on a broader scale. In support of this view, we noted that expression of a number of such factors, such as Serpin, was upregulated in the CSL-deficient cells. That loss of CSL enhances tumor development is further underlined by a recent study reporting that combined silencing of CSL and p53 in cancer-associated fibroblasts leads to stromal and cancer cell expansion ([@bib26]).

An unexpected consequence of removing CSL was the unlocking of a hypoxic response during normoxia, manifested by a post-transcriptional elevation of HIF1α protein levels and the upregulation of hypoxia-regulated genes such as *VEGF-A*, *STC2*, and *KLF8*. This is in line with previous reports on normoxic HIF1α protein stabilization ([@bib25], [@bib27]; for review see [@bib17], and adds to the emerging view of a multifaceted interplay between Notch and the cellular hypoxic response ([@bib1], [@bib19]). Notch1 ICD interacted with HIF1α, and it is noteworthy that blocking Notch ICD generation reduced the amount of HIF1α, raising the intriguing possibility that Notch ICD in some way plays a role in the observed HIF1α stabilization. Furthermore, the HIF1α protein levels in the CSL-deficient cells were reduced by DTT treatment, suggesting a role for redox potential, possibly linked to nitrosylation of HIF1α ([@bib25]) or destabilization of the ODD domain. The unleashing of a hypoxic response during normoxia may also be linked to the acquisition of aberrant cell morphology, a phenotype strongly reminiscent of the recently described polyploid giant cancer cell (PGCC) phenotype ([@bib37]). Interestingly, PGCC cells, which are endowed with cancer stem cell-like properties, were recently identified in a number of tumor contexts in response to hypoxia or chemical induction of the hypoxic response by CoCl~2~ ([@bib37]), suggesting that loss of CSL may lead to a PGCC-like state via upregulation of HIF1α. As PGCC cells are endowed with reduced proliferative rate in vitro combined with accelerated tumor growth capacity ([@bib37]), the induction of HIF1α protein levels in the CSL-deficient cells may underlie their enhanced growth rates, invasive capacity, and accelerated tumor growth.

In conclusion, the data in this report provide evidence for a role for CSL in controlling the cellular hypoxic response and cell cycle/cytokinesis as well as tumor growth. The data also indicate that CSL acts beyond only mediating Notch signaling.

Experimental Procedures {#sec4}
=======================

CRISPR/Cas9 Genome Editing {#sec4.1}
--------------------------

Designed guide RNA sequence targeting CSL (5′-AAACATTGTATATATCTGAC-3′) was cloned and ligated to the guide RNA vector (Addgene). Cells were co-transfected with the guide RNA vector and the Cas9 expression vector. Single-cell colonies were isolated and subjected to Western blot and DNA-sequencing analysis.

Mammary Fat Pad Xenograft {#sec4.2}
-------------------------

All animal procedures were approved by the Stockholm\'s North Ethical Committee for Animal Research (permit No N151/14). 1.5 × 10^6^ MDA-MB-231 control or CSL-deficient cells in culture media were orthotopically injected into the left and right fourth inguinal mammary fat pads of 4- to 6-week-old female immunodeficient NOD/SCID mice. Tumor growth and size was measured twice per week using calipers. Tumor volume was calculated according to the formula *L* × *W*^2^. Mice were euthanized at the third and fifth week after transplantation.

Statistical Analysis {#sec4.3}
--------------------

All statistical analyses were calculated by GraphPad Prism (ver. 6). For further details see [Supplemental Information](#app3){ref-type="sec"}.
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![CSL-Deficient Cells Accelerate Tumor Growth In Vivo\
(A) Schematic representation of CRISPR/Cas9 targeting of the CSL locus. The triangle points to the targeted exon. Red letters represent the guide RNA sequence and green letters the PAM sequence.\
(B) Western blot of CSL and β-actin (loading control) in control (CSL^+/+^) and two clones of CSL-deficient MDA-MB-231 cells (CSL^−/−^).\
(C) Notch reporter (12x CSL-EGFP) activity in control and CSL-deficient cells after transfection of 12xCSL-EGFP, Notch1-ICD (NICD), and CSL, as indicated. White arrows indicate cells expressing EGFP.\
(D) Average tumor volume at different time points after xenografting CSL^+/+^ or CSL^−/−^ cells. Eight tumors of four mice per group were analyzed.\
(E) Representative images and H&E stainings of control and CSL-deficient tumors.\
(F and G) Analysis of Ki67 (F) and cleaved Caspase-3 (cCasp3) (G) expression in MDA-MB-231^CSL+/+^ and CSL-deficient tumor sections (enlarged images to the right). At the bottom of each figure, the number of positive cells is quantified. Signals of at least four randomly chosen images from one tumor sample of each kind were counted.\
(H) Analysis and quantification of tumor growth in the chick chorioallantoic membrane (CAM) assay for CSL^+/+^ and CSL^−/−^ cells. At least five different tumors of each kind were measured.\
(I and J) Invasion and migration assays for CSL^+/+^ and CSL^−/−^ cells. This analysis is based on at least three independent experiments. Data are shown as percent of wild-type MDA-MB-231 DMSO control cells (set to 100%).\
Data are presented as mean ± SEM. ^∗^p ≤ 0.05; ^∗∗^p ≤ 0.01; ^∗∗∗^p ≤ 0.001. ns, not significant. Scale bars: 100 μm (C), 200 μm (E lower), 100 μm (F and G), and 75 μm (F and G inset).](gr1){#fig1}

![Unleashing Hypoxic Activation and Angiogenic Activity by CSL-Deficient Cells\
(A) Western blot of HIF1α, CSL, and β-actin (loading control) in control and CSL-deficient MDA-MB-231 cells under normoxic (left) and hypoxic (1% O~2~; right) conditions.\
(B and C) qPCR analysis of *HIF1α* (B) and *VEGF-A* (clone \#1) and *STC2* and *KLF8* (clone \#2) (C) mRNA expression in control and CSL^−/−^ cells. mRNA expression level analysis is based on three separate experiments.\
(D) Representative images of collagen IV (COLIV) and CD31 expression in control and CSL-deficient xenografts. Quantification of the CD31 staining is shown to the right. Signal quantification is based on at least three randomly chosen images from one tumor sample of each kind. Scale bar, 100 μm.\
(E and F) Western blot of HIF1α and β-actin in control and CSL-deficient MDA-MB-231 cells under normoxic or hypoxic conditions. Cells were cultured in the presence or absence of DTT (E) or DMSO/DAPT (F), as indicated.\
Data are presented as mean ± SD. ^∗^p ≤ 0.05; ^∗∗^p ≤ 0.01; ^∗∗∗^p ≤ 0.001. ns, not significant.](gr2){#fig2}

![Acquisition of a Polyploid Giant-Cell Phenotype in the CSL-Deficient Cells\
(A) Brightfield images of CSL^+/+^ and CSL^−/−^ cells (upper panel) and high-magnification view of CSL^+/+^ and CSL^−/−^ cells stained with DAPI and β-tubulin (lower panel). Giant cells are marked with arrows and polyploid cells are marked with arrowheads.\
(B) Proportion of cells without mitotic exit division and cells generating several daughter cells among CSL^+/+^ and CSL^−/−^ cells. At least 50 cells of each clone were analyzed.\
(C) Time-lapse images of control and CSL-deficient cells. The white arrowheads denote cells analyzed by time-lapse imaging.\
Scale bars: 100 μm (A upper), 50 μm (A lower), and 50 μm (C).](gr3){#fig3}

![A Notch-Independent Transcriptional Signature in the CSL-Deficient Cells\
(A) (Left) Heatmap of the 139 genes that constitute the Notch signature, i.e., genes which are upregulated by ligand (Jag1) stimulation and where gene expression is abrogated by DAPT. (Right) Heatmap of the 1,768 genes that were upregulated in CSL-deficient cells compared with control cells. Lower panel: Venn diagram showing the comparison of the Notch signature genes and genes upregulated in CSL-deficient cells.\
(B) PCA of genome-wide transcriptome analysis for CSL^+/+^ and CSL^−/−^ cells during ligand activation (Jag1) and inhibition by DAPT (n = 2 for each treatment).\
(C) PCA of genome-wide transcriptome analysis for CSL^+/+^ and CSL^−/−^ cells during in vitro culturing prior to tumor xenografting, the xenograft tumors, and when returned to in vitro culture after xenografting, as indicated.\
(D) Correlation plot of single-cell RNA-seq analysis from CSL^+/+^ and CSL^−/−^ cells in tumors from early (3 weeks) and late (5 weeks) stages.](gr4){#fig4}
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